Pharmacology and clinical pharmacology of methylarginines used as inhibitors of nitric oxide synthases

Current Pharmaceutical Design

Volumn 20, Issue 22, 2014, Pages 3530-3547

  Kittel, Anja ^a   Maas, Renke ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Alanine glyoxylate aminotransferase 2 (AGXT2); Asymmetric dimethylarginine (ADMA); Dimethylarginine dimethylaminohydrolase (DDAH); Monomethylarginine (L NMMA); Nitric oxide synthase (NOS); Symmetric dimethylarginine (SDMA)

Indexed keywords

ALANINE GLYOXYLATE AMINOTRANSFERASE; CARRIER PROTEIN; DIMETHYLARGININASE; N(G) METHYLARGININE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE INHIBITOR; ARGININE; DIMETHYLARGININE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENZYME INHIBITOR; NITRIC OXIDE;

ARTICLE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; ENZYME METABOLISM; HUMAN; IC50; NONHUMAN; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; METABOLISM; STRUCTURE ACTIVITY RELATION;

ANIMALS; ARGININE; ENZYME INHIBITORS; HUMANS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; OMEGA-N-METHYLARGININE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84911861771     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113196660750     Document Type: Article

References (114)

1. Hibbs JBJ, Taintor RR, Vavrin Z. Macrophage cytotoxicity: role for L-arginine deiminase and imino nitrogen oxidation to nitrite. Science 1987; 235: 473-6.
2. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for biological activity of endotehlium-derived relaxing factor. Nature 1987; 327: 524-6.
3. Palmer RMJ, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1987; 333: 664-6.
4. Rees DD, Palmer RMJ, Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci USA 1989; 86: 3375-8.
5. Aisaka K, Gross SS, Griffith OW, Levi R. NG-methylarginine, an inhibitor of endothelium-derived nitric oxide synthesis, is a potent pressor agent in the guinea pig: does nitric oxide regulate blood pressure in vivo? Biochem Biophys Res Commun 1989; 160: 881-6.
6. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-5.
7. Tsikas D, Sandmann J, Savva A, et al. Assessment of nitric oxide synthase activity in vitro and in vivo by gas chromatography-mass spectrometry. J Chromatogr B 2000; 742: 143-53.
8. Tsikas D, Böger RH, Sandmann J, Bode-Böger SM, Frölich JC. Endogenous nitric oxide synthase inhibitors are responsible for the L-arginine paradox. FEBS Lett 2000; 478: 1-3.
9. Kakimoto Y, Akazawa S. Isolation and identification of N-G,N-G-and N-G,N'-G-dimethyl-arginine, N-epsilon-mono-, di-, and trimethyllysine, and glucosylgalactosyl-and galactosyl-delta-hydroxylysine from human urine. J Biol Chem 1970; 245: 5751-8.
10. Paik WK, Kim S. Enzymatic methylation of protein fractions from calf thymus nuclei. Biochem Biophys Res Commun 1967; 29: 14-20.
11. Gary JD, Clarke S. RNA and protein interactions modulated by protein arginine methylation. Prog Nucleic Acid Res Mol Biol 1998; 61: 65-131.
12. Bulau P, Zakrzewicz D, Kitowska K, Wardega B, Kreuder J, Eickelberg O. Quantitative assessment of arginine methylation in free versus protein-incorporated amino acids in vitro and in vivo using protein hydrolysis and high-performance liquid chromatography. Biotechniques 2006; 40: 305-10.
13. Kakimoto Y, Matsuoka Y, Miyake M, Konishi H. Methylated amino acid residues of proteins of brain and other organs. J Neurochem 1975; 24: 893-902.
14. Cardounel AJ, Zweier JL. Endogenous methylarginines regulate neuronal nitric-oxide synthase and prevent excitotoxic injury. J Biol Chem 2002; 277: 33995-4002.
15. Bogle RG, MacAllister RJ, Whitley GS, Vallance P. Induction of NG-monomethyl-L-arginine uptake: a mechanism for differential inhibition of NO synthases? Am J Physiol 1995; 269: C750-6.
16. Teerlink T, Luo Z, Palm F, Wilcox CS. Cellular ADMA: regulation and action. Pharmacol Res 2009; 60: 448-60.
17. Böger R, Bode-Böger SM, Tsao PS, Lin PS, Chan JR, Cooke JP. An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. J Am Coll Cardiol 2000; 36: 2287-95.
18. Cardounel AJ, Cui H, Samouilov A, et al. Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function. J Biol Chem 2007; 282: 879-87.
19. Shirakawa T, Kako K, Shimada T, et al. Production of free methylarginines via the proteasome and autophagy pathways in cultured cells. Mol Med Rep 2011; 4: 615-20.
20. Maas R, Tan-Andreesen J, Schwedhelm E, Schulze F, Böger RH. A stable-isotope based technique for the determination of dimethylarginine dimethylaminohydrolase (DDAH) activity in mouse tissue. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 851: 220-8.
21. Leiper J, Nandi M, Torondel B, et al. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med 2007; 13: 198-203.
22. Achan V, Broadhead M, Malaki M, et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 2003; 23: 1455-9.
23. Servillo L, Giovane A, Cautela D, Castaldo D, Balestrieri ML. The methylarginines NMMA, ADMA, and SDMA are ubiquitous constituents of the main vegetables of human nutrition. Nitric Oxide 2013; 30: 43-8.
24. Teerlink T. ADMA metabolism and clearance. Vasc Med 2005; 10(Suppl 1): S73-81.
25. Fard A, Tuck CH, Donis JA, et al. Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol 2000; 20: 2039-44.
26. Rudolph TK, Ruempler K, Schwedhelm E, et al. Acute effects of various fast-food meals on vascular function and cardiovascular disease risk markers: the Hamburg Burger Trial. Am J Clin Nutr 2007; 86: 334-40.
27. Closs EI, Boissel JP, Habermeier A, Rotmann A. Structure and function of cationic amino acid transporters (CATs). J Membr Biol 2006; 213: 67-77.
28. Strobel J, Mieth M, Endreß B, et al. Interaction of the cardiovascular risk marker asymmetric dimethylarginine (ADMA) with the human cationic amino acid transporter 1 (CAT1). J Mol Cell Cardiol 2012.
29. Strobel J, König J, Maas R. Transport kinetics of asymmetric dimethylarginine (ADMA) by human cationic amino acid transporters (CAT1 and CAT2A). Naunyn Schmiedebergs Arch Pharmakol 2011; 383: 82-2.
30. Closs EI, Basha FZ, Habermeier A, Förstermann U. Interference of L-arginine analogues with L-arginine transport mediated by the y+ carrier hCAT-2B. Nitric oxide 1997; 1: 65-73.
31. Closs EI, Ostad MA, Simon A, et al. Impairment of the extrusion transporter for asymmetric dimethyl-L-arginine: a novel mechanism underlying vasospastic angina. Biochem Biophys Res Commun 2012; 423: 218-23.
32. McDermott JR. Studies on the catabolism of Ng-methylarginine, Ng, Ng-dimethylarginine and Ng, Ng-dimethylarginine in the rabbit. Biochem J 1976; 154: 179-84.
33. Ogawa T, Kimoto M, Watanabe H, Sasaoka K. Metabolism of NG,NG-and NG,N'G-dimethylarginine in rats. Arch Biochem Biophys 1987; 252: 526-37.
34. Ogawa T, Kimoto M, Sasaoka K. Dimethylarginine:pyruvate aminotransferase in rats. Purification, properties, and identity with alanine:glyoxylate aminotransferase 2. J Biol Chem 1990; 265: 20938-45.
35. Caplin B, Wang Z, Slaviero A, et al. Alanine-glyoxylate aminotransferase-2 metabolizes endogenous methylarginines, regulates NO, and controls blood pressure. Arterioscler Thromb Vasc Biol 2012; 32: 2892-900.
36. Rodionov RN, Murry DJ, Vaulman SF, Stevens JW, Lentz SR. Human alanine-glyoxylate aminotransferase 2 lowers asymmetric dimethylarginine and protects from inhibition of nitric oxide production. J Biol Chem 2010; 285: 5385-91.
37. Ogawa T, Kimoto M, Sasaoka K. Purification and properties of a new enzyme, NG,NG-dimethylarginine dimethylaminohydrolase, from rat kidney. J Biol Chem 1989; 264: 10206-9.
38. Ogawa T, Kimoto M, Sasaoka K. Occurrence of a new enzyme catalyzing the direct conversion of NG,NG-dimethyl-L-arginine to L-citrulline in rats. Biochem Biophys Res Commun 1987; 148: 671-7.
39. Arrigoni F, Ahmetaj B, Leiper J. The biology and therapeutic potential of the DDAH/ADMA pathway. Curr Pharm Des 2010; 16: 4089-102.
40. Tran CT, Leiper JM, Vallance P. The DDAH/ADMA/NOS pathway. Atheroscler Suppl 2003; 4: 33-40.
41. Leiper JM, Santa Maria J, Chubb A, et al. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J 1999; 343 Pt 1: 209-14.
42. Wang D, Gill PS, Chabrashvili T, et al. Isoform-specific regulation by N(G),N(G)-dimethylarginine dimethylaminohydrolase of rat serum asymmetric dimethylarginine and vascular endothelium-derived relaxing factor/NO. Circ Res 2007; 101: 627-35.
43. Hu X, Atzler D, Xu X, et al. Dimethylarginine dimethylaminohydrolase-1 is the critical enzyme for degrading the cardiovascular risk factor asymmetrical dimethylarginine. Arterioscler Thromb Vasc Biol 2011; 31: 1540-6.
44. Geldmacher F, Lüneburg N, Bernges I, et al. A global knock out of the dimethylarginine dimethylaminohydrolase 2 (DDAH2) gene in mice has no impact on aortic endothelial function and viability. Naunyn Schmiedebergs Arch Pharmakol 2011; 383: 63-63.
45. Hu X, Xu X, Zhu G, et al. Vascular endothelial-specific dimethylarginine dimethylaminohydrolase-1-deficient mice reveal that vascular endothelium plays an important role in removing asymmetric dimethylarginine. Circulation 2009; 120: 2222-9.
46. Dayoub H, Achan V, Adimoolam S, et al. Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence. Circulation 2003; 108: 3042-7.
47. Jacobi J, Sydow K, von Degenfeld G, et al. Overexpression of dimethylarginine dimethylaminohydrolase reduces tissue asymmetric dimethylarginine levels and enhances angiogenesis. Circulation 2005; 111: 1431-8.
48. Tanaka M, Sydow K, Gunawan F, et al. Dimethylarginine dimethylaminohydrolase overexpression suppresses graft coronary artery disease. Circulation 2005; 112: 1549-56.
49. Konishi H, Sydow K, Cooke JP. Dimethylarginine dimethylaminohydrolase promotes endothelial repair after vascular injury. J Am Coll Cardiol 2007; 49: 1099-105.
50. Dayoub H, Rodionov RN, Lynch C, et al. Overexpression of dimethylarginine dimethylaminohydrolase inhibits asymmetric dimethylarginine-induced endothelial dysfunction in the cerebral circulation. Stroke 2008; 39: 180-4.
51. Rodionov RN, Dayoub H, Lynch CM, et al. Overexpression of dimethylarginine dimethylaminohydrolase protects against cerebral vascular effects of hyperhomocysteinemia. Circ Res 2010; 106: 551-8.
52. Jacobi J, Maas R, Cardounel AJ, et al. Dimethylarginine dimethylaminohydrolase overexpression ameliorates atherosclerosis in apolipoprotein E-deficient mice by lowering asymmetric dimethylarginine. Am J Pathol 2010; 176: 2559-70.
53. Sydow K, Mondon CE, Schrader J, Konishi H, Cooke JP. Dimethylarginine dimethylaminohydrolase overexpression enhances insulin sensitivity. Arterioscler Thromb Vasc Biol 2008; 28: 692-7.
54. Jacobi J, Maas R, Cordasic N, et al. Role of asymmetric dimethylarginine for angiotensin II-induced target organ damage in mice. Am J Physiol Heart Circ Physiol 2008; 294: H1058-H1066.
55. Hasegawa K, Wakino S, Tatematsu S, et al. Role of asymmetric dimethylarginine in vascular injury in transgenic mice overexpressing dimethylarginie dimethylaminohydrolase 2. Circ Res 2007; 101: e2-10.
56. Kielstein JT, Salpeter SR, Bode-Boeger SM, Cooke JP, Fliser D. Symmetric dimethylarginine (SDMA) as endogenous marker of renal function--a meta-analysis. Nephrol Dial Transplant 2006; 21: 2446-51.
57. Nijveldt RJ, Van Leeuwen PA, Van Guldener C, Stehouwer CD, Rauwerda JA, Teerlink T. Net renal extraction of asymmetrical (ADMA) and symmetrical (SDMA) dimethylarginine in fasting humans. Nephrol Dial Transplant 2002; 17: 1999-2002.
58. Siroen MPC, van der Sijp JRM, Teerlink T, van Schaik C, Nijveldt RJ, van Leeuwen PAM. The human liver clears both asymmetric and symmetric dimethylarginine. Hepatology 2005; 41: 559-65.
59. Kielstein JT, Impraim B, Simmel S, et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 2004; 109: 172-7.
60. Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989; 8670: 997-1000.
61. Petros A, Lamb G, Leone A, Moncada S, Bennett D, Vallance P. Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res 1994; 28: 34-9.
62. Brett SE, Cockcroft JR, Mant TGK, Ritter JM, Chowienczyk PJ. Haemodynamic effects of inhibition of nitric oxide synthase and of L-arginine at rest and during exercise. J Hypertens 1998; 16: 429-35.
63. White RP, Hindley C, Bloomfield PM, et al. The effect of the nitric oxide synthase inhibitor L-NMMA on basal CBF and vasoneuronal coupling in man: a PET study. J Cereb Blood Flow Metab 1999; 19: 673-8.
64. Mayer BX, Mensik C, Krishnaswami S, et al. Pharmacokinetic-pharmacodynamic profile of systemic nitric oxide-synthase inhibition with L-NMMA in humans. Br J Clin Pharmacol 1999; 47: 539-44.
65. Cotter G, Kaluski E, Blatt A, et al. L-NMMA (a nitric oxide synthase inhibitor) is effective in the treatment of cardiogenic shock. Circulation 2000; 101: 1358-61.
66. Hjorth LL, Klingenberg IH, Olesen J. A dose-response study of nitric oxide synthase inhibition in different vascular beds in man. Eur J Clin Pharmacol 2003; 59: 499-505.
67. Dzavík V, Cotter G, Reynolds HR, et al. Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study. Eur Heart J 2007; 28: 1109-16.
68. TRIUMPH Investigators, Alexander JH, Reynolds HR, et al. Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA 2007; 297: 1657-66.
69. Kielstein JT, Simmel S, Bode-Böger SM, et al. Subpressor dose asymmetric dimethylarginine modulates renal function in humans through nitric oxide synthase inhibition. Kidney Blood Press Res 2004; 27: 143-7.
70. Kielstein JT, Donnerstag F, Gasper S, et al. ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke 2006; 37: 2024-9.
71. von Leitner EC, Klinke A, Atzler D, et al. Pathogenic cycle between the endogenous nitric oxide synthase inhibitor asymmetrical dimethylarginine and the leukocyte-derived hemoprotein myeloperoxidase. Circulation 2011; 124: 2735-45.
72. Albsmeier J. Bedeutung endogener Inhibitoren der NO-Synthase für kardiovaskuläre Erkrankungen und ihre pharmakologische Therapie (Relevance of endogenous NOS inhibitors for cardiovascular disease and its therapy) [Thesis FBCh 2550]. Hamburg: University of Hamburg 2004.
73. Pollock JS, Förstermann U, Mitchell JA, et al. Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells. Proc Natl Acad Sci USA 1991; 88: 10480-4.
74. Böger RH. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res 2003; 59: 824-33.
75. Lai YL, Aoyama S, Nagai R, Miyoshi N, Ohshima H. Inhibition of L-arginine metabolizing enzymes by L-arginine-derived advanced glycation end products. J Clin Biochem Nutr 2010; 46: 177-85.
76. Reif DW, McCreedy SS. N-nitro-L-arginine and N-monomethyl-L-arginine exhibit a different pattern of inactivation toward the three nitric oxide synthases. Arch Biochem Biophys 1995; 320: 170-6.
77. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and inhibition. Biochem J 2001; 357: 593-615.
78. Faraci WS, Nagel AA, Verdries KA, et al. 2-Amino-4-methylpyridine as a potent inhibitor of inducible NO synthase activity in vitro and in vivo. Br J Pharmacol 1996; 119: 1101-8.
79. Li W, Xue J, Niu C, et al. Synergistic neuroprotection by bis(7)-tacrine via concurrent blockade of N-methyl-D-aspartate receptors and neuronal nitric-oxide synthase. Mol Pharmacol 2007; 71: 1258-67.
80. Bredt DS, Snyder SH. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc Natl Acad Sci USA 1990; 87: 682-5.
81. Schmidt HHW, Pollock JS, Nakane M, Gorsky LD, Förstermann U, Murad F. Purification of a soluble isoform of guanylyl cyclase-activating-factor synthase. Proc Natl Acad Sci USA 1991; 88: 365-9.
82. Sandmann J. Untersuchungen zur Bedeutung der S-Transnitrosylierungs-Reaktion für die Bildung, den Metabolismus und die Vermittlung der biologischen Aktivitäten von NO und S-Nitroso-Substanzen. Hannover: University of Hannover 2000.
83. Faraci FM, Brian JE, Heistad DD. Response of cerebral blood vessels to an endogenous inhibitor of nitric oxide synthase. Am J Physiol Heart Circ Physiol 1995; 269: H1522-H1524.
84. Barjavel MJ, Bhargava HN. Effect of opioid receptor agonists on nitric oxide synthase activity in rat cerebral cortex homogenate. Neurosci Lett 1994; 181: 27-30.
85. Klatt P, Schmidt K, Brunner F, Mayer B. Inhibitors of brain nitric oxide synthase. Binding kinetics, metabolism, and enzyme inactivation. J Biol Chem 1994; 269: 1674-80.
86. Sorrentino R, Sautebin L, Pinto A. Effect of methylguanidine, guanidine and structurally related compounds on constitutive and inducible nitric oxide synthase activity. Life Sci 1997; 61: 1283-91.
87. Stuehr DJ, Cho HJ, Kwon NS, Weise MF, Nathan CF. Purification and characterization of the cytokine-induced macrophage nitric oxide synthase: An FAD-and FMN-containing flavoprotein. Proc Natl Acad Sci USA 1991; 88: 7773-7.
88. Hevel JM, White KA, Marletta MA. Purification of the inducible murine macrophage nitric oxide synthase. Identification as a flavoprotein. J Biol Chem 1991; 226: 22789-91.
89. Tang X, Zhou D, Kang G. Induction and kinetic characterization of nitric oxide synthase in hepatocytes. Zhonghua Gan Zang Bing Za Zhi 2001; 9: 169-71.
90. Yui Y, Hattori R, Kosuga K, Eizawa H, Hiki K, Kawai C. Purification of nitric oxide synthase from rat macrophages. J Biol Chem 1991; 226: 12544-7.
91. Gross SS, Stuehr DJ, Aisaka K, Jaffe EA, Levi R, Griffith OW. Macrophage and endothelial cell nitric oxide synthesis: cell-type selective inhibition by NG-aminoarginine, NG-nitroarginine and NG-methylarginine. Biochem Biophys Res Commun 1990; 170: 96-103.
92. Moore PK, al-Swayeh OA, Chong NWS, Evans RA, Gibson A. LNG-nitro arginine (L-NOARG), a novel, L-arginine-reversible inhibitor of endothelium-dependent vasodilation in vitro. Br J Pharmacol 1990; 99: 408-12.
93. Rees DD, Palmer RM, Schulz R, Hodson HF, Moncada S. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol 1990; 101: 746-52.
94. MacAllister RJ, Whitley G, Vallance P. Effects of guanidino and uremic compounds on nitric oxide pathways. Kidney Int 1994; 45: 737-42.
95. Segarra G, Medina P, Vila JM, Chuan P, Domenech C, Torondel B, et al. Inhibition of nitric oxide activity by arginine analogs in human renal arteries. Am J Hypertens 2001; 14: 1142-8.
96. Gardiner SM, Compton AM, Bennett T, Palmer RM, Moncada S. Control of regional blood flow by endothelium-derived nitric oxide. Hypertension 1990; 15: 486-92.
97. Gardiner SM, Kemp PA, Bennett T, Palmer RM, Moncada S. Regional and cardiac haemodynamic effects of NG, NG,dimethyl-L-arginine and their reversibility by vasodilators in conscious rats. Br J Pharmacol 1993; 110: 1457-64.
98. Suda O, Tsutsui M, Morishita T, et al. Asymmetric dimethyl-arginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of renin-angiotensin system and oxidative stress. Arterioscler Thromb Vasc Biol 2004; 24: 1682-8.
99. Xiao HB, Yang ZC, Jia SJ, et al. Effect of asymmetric dimethylarginine on atherogenesis and erythrocyte deformability in apolipoprotein E deficient mice. Life sci 2007; 81: 1-7.
100. Wells SM, Buford MC, Migliaccio CT, Holian A. Elevated asymmetric dimethylarginine alters lung function and induces collagen deposition in mice. Am J Respir Cell Mol Biol 2009; 40: 179-88.
101. Schwedhelm E, Xanthakis V, Maas R, et al. Asymmetric dimethylarginine reference intervals determined with liquid chromatography-tandem mass spectrometry: results from the Framingham offspring cohort. Clin Chem 2009; 55: 1539-45.
102. Schwedhelm E, Xanthakis V, Maas R, et al. Plasma symmetric dimethylarginine reference limits from the Framingham offspring cohort. Clin Chem Lab Med 2011; 49: 1907-10.
103. Wang Z, Tang WH, Cho L, Brennan DM, Hazen SL. Targeted metabolomic evaluation of arginine methylation and cardiovascular risks: potential mechanisms beyond nitric oxide synthase inhibition. Arterioscler Thromb Vasc Biol 2009; 29: 1383-91.
104. Böger RH, Maas R, Schulze F, Schwedhelm E. Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality--an update on patient populations with a wide range of cardiovascular risk. Pharmacol Res 2009; 60: 481-7.
105. Maas R, Schulze F, Baumert J, et al. Asymmetric dimethylarginine, smoking, and risk of coronary heart disease in apparently healthy men: prospective analysis from the population-based Monitoring of Trends and Determinants in Cardiovascular Disease/Kooperative Gesundheitsforschung in der Region Augsburg study and experimental data. Clin Chem 2007; 53: 693-701.
106. Valkonen VP, Paiva H, Salonen JT, et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001; 358: 2127-8.
107. Schnabel R, Blankenberg S, Lubos E, et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 2005; 97: e53-9.
108. Aucella F, Maas R, Vigilante M, et al. Methylarginines and mortality in patients with end stage renal disease: a prospective cohort study. Atherosclerosis 2009; 207: 541-5.
109. Zoccali C, Bode-Böger S, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358: 2113-7.
110. Nijveldt RJ, Teerlink T, Van Der Hoven B, et al. Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality. Clin Nutr 2003; 22: 23-30.
111. Böger RH, Sullivan LM, Schwedhelm E, et al. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 2009; 119: 1592-600.
112. Pizzarelli F, Maas R, Dattolo P, et al. Asymmetric dimethyl-arginine predicts survival in the elderly. Age (Dordr) 2013.
113. Schulze F, Carter AM, Schwedhelm E, et al. Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke. Atherosclerosis 2010; 208: 518-23.
114. Maas R, Böger R, Lüneburg N. ADMA and the role of the genes: lessons from genetically modified animals and human gene polymorphisms. Pharmacol Res 2009; 60: 475-80.